{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-015045","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.266882+00:00","generated_at":"2026-06-18T22:25:02.652261+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Hoth Therapeutics receives FDA clearance to proceed with Phase 2a trial of HT-001 for EGFR inhibitor skin toxicities","bullets":["FDA completed safety review and permitted IND for HT-001 to treat rash and skin disorders from EGFR inhibitor therapy.","Phase 2a trial (CLEER) is a randomized, placebo-controlled, parallel dose-ranging study.","European patent application filed for compositions and methods treating lung inflammation."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-015045","json":"https://secwatch.observer/filing/0001213900-23-015045.json","markdown":"https://secwatch.observer/filing/0001213900-23-015045.md","text":"https://secwatch.observer/filing/0001213900-23-015045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000121390023015045/0001213900-23-015045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000121390023015045/ea174379-8k_hoththera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:25:02.652261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}